


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**CHANGE OF COMPANY SECRETARY AND
AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”) announces that with effect from 13 January, 2026:

1. Mr. Chan Oi Nin Derek (“**Mr. Chan**”) has resigned as the Company Secretary of the Company and ceased to act as an authorised representative (“**Authorised Representative**”) of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and
2. Ms. Lai Kuen (“**Ms. Lai**”) has been appointed to fill the positions of Company Secretary and Authorised Representative of the Company.

Mr. Chan has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

Ms. Lai joined the Company in September 2025, and prior to joining the Company, she worked in PricewaterhouseCoopers Zhong Tian CPAs Limited Company, CLSA Research Limited and a number of companies listed on the Stock Exchange, and has over 17 years of experience in financial audit, capital markets, information disclosure, corporate governance and company secretarial matters. Ms. Lai graduated from Guanghua School of Management, Peking University majoring in accounting with a bachelor degree of management. She was awarded a master degree in business administration from The University of Hong Kong. Ms. Lai is a Chartered Secretary, Chartered Governance Professional and an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

The Board would like to express its sincere gratitude to Mr. Chan for his valuable contribution to the Company during his long period of service and welcome Ms. Lai on her appointment.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 January 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.